Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension

European Heart Journal

Volumn 34, Issue 6, 2013, Pages

  Dorenkamp, Marc ^a   Bonaventura, Klaus ^b,c   Leber, Alexander W ^d   Boldt, Julia ^a   Sohns, Christian ^e   Boldt, Leif Hendrik ^a   Haverkamp, Wilhelm ^a   Frei, Ulrich ^a   Roser, Mattias ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF POTSDAM   (Germany)

^c KLINIKUM ERNST VON BERGMANN   (Germany)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cardiovascular disease; Cost effectiveness; Prevention; Renal sympathetic denervation; Resistant hypertension

Indexed keywords

AGED; ARTICLE; CATHETER; COST EFFECTIVENESS ANALYSIS; DEATH; FEMALE; HUMAN; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; PRIORITY JOURNAL; QUALITY OF LIFE; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SYMPATHECTOMY; URINARY CATHETERIZATION;

EID: 84873643430     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs355     Document Type: Article

References (73)

1. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252.
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.
4. Perkovic V, Huxley R, Wu Y, Prabhakaran D, MacMahon S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007; 50:991-997.
5. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371: 1513-1518.
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL, The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension, The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536.
7. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:e510-e526.
8. Fagard RH. Resistant hypertension. Heart 2012;98:254-261.
9. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009;361:932-934.
10. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-1281.
11. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-1909.
12. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011;57:911-917.
13. Wisløff T, Selmer RM, Halvorsen S, Kristiansen IS. Norwegian Cardiovascular Disease Model (NorCAD)-a simulation model for estimating health benefits and cost consequences of cardiovascular interventions. Rapport No. 23-2008. Oslo, Norway: Norwegian Knowledge Centre for the Health Services; 2008.
14. Wisløff T, Selmer RM, Halvorsen S, Fretheim A, Norheim OF, Kristiansen IS. Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease-a cost-effectiveness analysis. BMC Cardiovasc Disord 2012;12:26.
15. Robert Koch Institute. 'Coronary heart disease (CHD) and acute myocardial infarction.' Federal Health Reporting Publication No. 33 http://www.rki.de/EN/ Content/Health-Reporting/Booklets/herzkrankheit-inhalt.html (22 April 2012).
16. Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann KG, von Stockert TR. A prospective community-based study of stroke in Germany-the Erlangen Stroke Project (ESPro): incidence and case fatality at 1, 3, and 12 months. Stroke 1998;29: 2501-2506.
17. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, Sutton GC. Incidence and aetiology of heart failure; a population-based study. Eur Heart J 1999;20:421-428.
18. Frei U, Schober-Halstenberg HJ. Nierenersatztherapie in Deutschland. Bericht uber Dialysebehandlung und Nierentransplantation in Deutschland 2006/2007. Berlin, Germany: QuaSi-Niere gGmbH; 2008.
19. DESTATIS-Federal Statistical Office of Germany (Statistisches Bundesamt). Official German lifetables, 2008/2010. https://www.destatis.de/DE/ZahlenFakten/ GesellschaftStaat/Bevoelkerung/Sterbefaelle/Tabellen/SterbetafelDeutschland. html (20 April 2012).
20. Federal Health Monitoring System (Gesundheitsberichterstattung des Bundes). Deaths, cases per 100,000 inhabitants (2010). http://www.gbe-bund.de/ oowa921nstall/servlet/oowa/aw92/dboowasys921.xwdevkitlxwd-init?gbe.isgbetol/ xs-start-neu/&p-aid=3&p-aid=47114833&nummer=8&p-sprache= E&pjndsp=5781437&p-aid=28338986 (20 April 2012).
21. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM; SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
22. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005;165:923-928.
23. Thamm M. Blood pressure in Germany: current status and trends. Gesundheitswesen 1999;61:90-93.
24. Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, Fioretti PM, Simoons ML, Battler A. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002;23:1190-1201.
25. Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, van 't Hof AW, Suryapranata H. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999;341: 1413-1419.
26. de Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, Bendermacher PE, Michels HR, Sanders GT, Tijssen JG, Verheugt FW; Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005;353:1095-1104.
27. Budaj A, Flasinska K, Gore JM, Anderson FA Jr, Dabbous OH, Spencer FA, Goldberg RJ, Fox KA; GRACE Investigators. Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: findings from a Global Registry of Acute Coronary Events. Circulation 2005;111: 3242-3247.
28. Fox KA, Goodman SG, Anderson FA Jr, Granger CB, Moscucci M, Flather MD, Spencer F, Budaj A, Dabbous OH, Gore JM; GRACE Investigators. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24: 1414-1424.
29. Heller G, Babitsch B, Gunster C, Mo ckel M. Mortality following myocardial infarction in women and men. Dtsch Arztebl Int 2008;105:279-285.
30. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, Abildgaard U, Pedersen F, Madsen JK, Grande P, Villadsen AB, Krusell LR, Haghfelt T, Lomholt P, Husted SE, Vigholt E, Kjaergard HK, Mortensen LS; DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733-742.
31. Daly C, Clemens F, Lopez Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM; Euro Heart Survey Investigators. Gender differences in the management and clinical outcome of stable angina. Circulation 2006;113:490-498.
32. Palm F, Urbanek C, Rose S, Buggle F, Bode B, Hennerici MG, Schmieder K, Inselmann G, Reiter R, Fleischer R, Piplack KO, Safer A, Becher H, Grau AJ. Stroke Incidence and Survival in Ludwigshafen am Rhein, Germany: the Ludwigshafen Stroke Study (LuSSt). Stroke 2010;41:1865-1870.
33. Rosolova H, Cech J, Simon J, Spinar J, Jandova R, Widimsky' sen J, Holubec L, Topolcan O. Short to long term mortality of patients hospitalised with heart failure in the Czech Republic-a report from the EuroHeart Failure Survey. Eur J Heart Fail 2005;7:780-783.
34. Villar E, Remontet L, Labeeuw M, Ecochard R. Effect of age, gender, and diabetes on excess death in end-stage renal failure. J Am Soc Nephrol 2007;18:2125-2134.
35. Madsen MM, Busk M, Søndergaard HM, Bøttcher M, Mortensen LS, Andersen HR, Nielsen TT; DANAMI-2 Investigators. Does diabetes mellitus abolish the beneficial effect of primary coronary angioplasty on long-term risk of reinfarction after acute ST-segment elevation myocardial infarction compared with fibrinolysis? (A DANAMI-2 substudy). Am J Cardiol 2005;96:1469-1475.
36. Dickstein K, Gleim GW, Snapinn S, James MK, Kjekshus J; OPTIMAAL Study Group. The impact of morbid events on survival following hospitalization for complicated myocardial infarction. Eur J Heart Fail 2006;8:74-80.
37. Garc?'a-Garc?'a C, Subirana I, Sala J, Bruguera J, Sanz G, Valle V, Aro' s F, Fiol M, Molina L, Serra J, Marrugat J, Elosua R. Long-term prognosis of first myocardial infarction according to the electrocardiographic pattern (ST elevation myocardial infarction, non-ST elevation myocardial infarction and non-classified myocardial infarction) and revascularization procedures. Am J Cardiol 2011;108:1061-1067.
38. Clayton TC, Lubsen J, Pocock SJ, Voko' Z, Kirwan BA, Fox KA, Poole-Wilson PA. Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients. BMJ 2005;331: 869.
39. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006;27:2784-2814.
40. van Wijk I, Kappelle LJ, van Gijn J, Koudstaal PJ, Franke CL, Vermeulen M, Gorter JW, Algra A; LiLAC Study Group. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 2005;365:2098-2104.
41. Touze' E, Varenne O, Chatellier G, Peyrard S, Rothwell PM, Mas JL. Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis. Stroke 2005;36:2748-2755.
42. Hillen T, Coshall C, Tilling K, Rudd AG, McGovern R, Wolfe CD; South London Stroke Register. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke 2003;34:1457-1463.
43. Peeters A, Mamun AA, Willekens F, Bonneux L. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002;23:458-466.
44. Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A, Grobbee DE. The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J 2001;22:1318-1327.
45. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye' LA, Goldhaber SZ, Pfeffer MA. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-257.
46. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997;29:1074-1080.
47. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442-463.
48. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
49. Kobayashi M, Hirawa N, Yatsu K, Kobayashi Y, Yamamoto Y, Saka S, Andoh D, Toya Y, Yasuda G, Umemura S. Relationship between silent brain infarction and chronic kidney disease. Nephrol Dial Transplant 2009;24:201-207.
50. Stein JD, Brown GC, Brown MM, Sharma S, Hollands H, Stein HD. The quality of life of patients with hypertension. J Clin Hypertens (Greenwich) 2002;4:181-188.
51. Nease RF Jr, Kneeland T, O'Connor GT, Sumner W, Lumpkins C, Shaw L, Pryor D, Sox HC. Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. JAMA 1995;273:1185-1190.
52. Tsevat J, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, Lee TH. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making 1993;13:161-165.
53. Dorman P, Dennis M, Sandercock P. Are the modified 'simple questions' a valid and reliable measure of health related quality of life after stroke? United Kingdom Collaborators in the International Stroke Trial. J Neurol Neurosurg Psychiatry 2000;69:487-493.
54. Young KC, Teeters JC, Benesch CG, Bisognano JD, Illig KA. Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator. J Clin Hypertens (Greenwich) 2009;11:555-563.
55. Hornberger JC, Best JH, Garrison LP Jr. Cost-effectiveness of repeat medical procedures: kidney transplantation as an example. Med Decis Making 1997;17: 363-372.
56. Kroeker A, Clark WF, Heidenheim AP, Kuenzig L, Leitch R, Meyette M, Muirhead N, Ryan H, Welch R, White S, Lindsay RM. An operating cost comparison between conventional and home quotidian hemodialysis. Am J Kidney Dis 2003;42:49-55.
57. Cohen DJ, Taira DA, Berezin R, Cox DA, Morice MC, Stone GW, Grines CL. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation 2001;104:3039-3045.
58. German Institute for the Hospital Remuneration System (InEK). G-DRG-System 2012. http://www.g-drg.de/cms/G-DRG-System-2012/Fallpauschalen- Katalog (22 April 2012).
59. Rote Liste Service GmbH. Rote Liste 2012. Arzneimittelinformationen fur Deutschland. Frankfurt am Main, Germany: Rote Liste Service GmbH; 2012.
60. Association of Statutory Health Insurance Physicians Berlin. Standard service volumes 01/2012. http://www.kvberlin.de/20praxis/30abrechnung-honorar/ 90honorarverteilung/rlv-fallwerte1201.pdf (22 April 2012).
61. Bonaventura K, Leber AW, Sohns C, Roser M, Boldt LH, Kleber FX, Haverkamp W, Dorenkamp M. Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease. Clin Res Cardiol 2012;101:573-584.
62. The National Institute for Health and Clinical Excellence. Social Value Judgments: Principles for the Development of NICE Guidance, 2nd edn. London: The National Institute for Health and Clinical Excellence; 2008.
63. Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, Luft FC, Haller H, Menne J, Engeli S, Ceral J, Eckert S, Erglis A, Narkiewicz K, Philipp T, de Leeuw PW. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010;56: 1254-1258.
64. Johannesson M, Jonsson B. A review of cost-effectiveness analyses of hypertension treatment. Pharmacoeconomics 1992;1:250-264.
65. Montgomery AA, Fahey T, Ben-Shlomo Y, Harding J. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertens 2003;21:1753-1759.
66. Krum H, Barman N, Schlaich M, Sobotka P, Esler M, Mahfoud F. Long-term followup of catheter-based renal sympathetic denervation for resistant hypertension confirms durable blood pressure reduction. J Am Coll Cardiol 2012;59:E1704.
67. Greving JP, Buskens E, Koffijberg H, Algra A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation 2008;117: 2875-2883.
68. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Bohm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011;123:1940-1946.
69. Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, Linz D, Schmieder R, Rump LC, Kindermann I, Sobotka PA, Krum H, Scheller B, Schlaich M, Laufs U, Bohm M. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012; 60:419-424.
70. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M, Hoppe UC. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012;59: 901-909.
71. Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Bohm M, Krum H. Sympatho-renal axis in chronic disease. Clin Res Cardiol 2011;100:1049-1057.
72. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358: 1887-1898.
73. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C. ESH position paper: renal denervation-an interventional therapy of resistant hypertension. J Hypertens 2012;30: 837-841.